Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Power Of The Dream Ventures, Inc. (PWRV) Subsidiary Highlights Peer-Reviewed Publication Covering Company's Potential Cure Of HIV

Genetic Immunity, a wholly owned subsidiary of Power of the Dream Ventures, today announced the peer-reviewed publication, "Nanomedicine applications Towards the Cure of HIV," covering the company's nanotechnology and detailing its potential for the cure of HIV.

To provide background of the technology the company explains: the scientists of Genetic Immunity described their research for the cure of HIV in an article in the May 1999 issue of the New England Journal of Medicine. The article features "the Berlin patient," the first patient whose immune system was boosted to control HIV after he elected to stop his daily drug treatment (www.nejm.org/doi/full/10.1056/NEJM199905...). It was observation of this scenario that the company says inspired development of DermaVir, a drug that boosts the immune system to specifically recognize and kill HIV infected cells. Fast-forward to-date, and DermaVir is the most advanced nanomedicine developed for the cure of HIV, says Genetic Immunity.

"We have about 30 potent HIV drugs suppressing viral load, but we do not have any to eliminate the infected cells from the reservoirs. To cure HIV we need new drugs to activate these infected cells and to kill them. In our manuscript we described the new drugs that are needed and the strategy that will result in the cure of HIV. One of these new essential drugs for HIV eradication is DermaVir, our lead HIV-specific immunotherapeutic product," Genetic Immunity CEO Dr. Julianna Lisziewicz stated in today's press release.

Dr. Lisziewicz explains that in contrast to daily oral drugs for the treatment of HIV, DermaVir is administered only a few times a year with four patches. In the company's clinical trials, DermaVir was shown safe as a placebo and effective in inducing long-lasting HIV-specific T cell production.

"Our GIEU006 phase II trial demonstrated significant killing of HIV-infected cells, producing 70 percent viral load reduction compared to a placebo. Our results suggest that DermaVir provides the immunologic drug component toward the eradication of HIV," Dr. Lisziewicz concluded.

For more information visit geneticimmunity.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net